July 2026– date –
-
Antibody-Drug Conjugates Evolve from ‘Magic Bullet’ to Standard of Care in Solid Tumors, T-DXd and Combination Therapies Set New Benchmarks
Binaytara USA Overview Antibody-Drug Conjugates (ADCs) have significantly evolved in solid tumor treatment, transitioning from a 'magic bullet' concept to a 'standard of care.' Globally, over 12 ADCs are approved, with more than 300 in c... -
Frontiers Review Highlights RNA-Based Drugs’ Transformative Role in Modern Medicine, Emphasizing siRNA, mRNA, and ASO Delivery Strategies
Frontiers Switzerland Overview A Frontiers review comprehensively outlines the evolution of RNA therapeutics into innovative medical approaches by directly targeting disease-related RNA molecules. The review highlights the mechanisms of ... -
Tango Therapeutics Unveils TNG961, First Selective Oral HBS1L Molecular Glue Degrader for FOCAD-Deleted Cancers, a New Precision Oncology Strategy
AACR Journals (Cancer Discovery) USA Overview Tango Therapeutics announced the development of TNG961, the first selective oral HBS1L molecular glue degrader targeting FOCAD-deleted cancers. TNG961 induces translational arrest by disrupti... -
Hongene Biotech: Scaling Oligonucleotide Manufacturing Crucial for Surging siRNA Demand in Cardiometabolic Diseases
Hongene Biotech China Overview Hongene Biotech emphasizes the critical need for a dramatic scale-up in oligonucleotide manufacturing to meet the surging demand for siRNA therapeutics targeting cardiometabolic diseases. Driven by the succ... -
siRNA Overcomes Gene Silencing Challenges with LNP and GalNAc Conjugation, Expanding Therapeutic Applications
Inside Therapeutics USA Overview Inside Therapeutics details how siRNA, while offering transformative gene silencing, is overcoming delivery challenges through lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) conjugation tech... -
Investor Focus: RNA Platform Success Hinges on Extrahepatic Delivery Capabilities Beyond the Liver
Bioprocess Online USA Overview Bioprocess Online highlights that a key question for investors evaluating RNA therapeutic platforms is the ability to effectively deliver RNA to diverse extrahepatic organs. While current successes often le... -
Patient-Specific Lymphoid Organ Chips Recapitulate mRNA Vaccine Immune Response, Accelerating Preclinical Evaluation
Wyss Institute USA Overview Researchers at the Wyss Institute have developed an innovative technology capable of replicating mRNA vaccine-induced immune responses on patient-specific Lymphoid Organ Chips. This human-derived, ex vivo mode... -
Novartis Reverses ADC Holdout with $1.5B Myricx Deal Amid Sustained M&A Boom in ADC Market
Fierce Biotech USA Overview Novartis, previously hesitant about Antibody-Drug Conjugates (ADCs), has committed up to $1.5 billion to Myricx Bio, signaling a strategic shift into the burgeoning ADC market. This move follows a series of hi... -
RNA Medicines Enter ‘Second Act’ Post-COVID-19, Focusing on Extrahepatic Delivery Beyond the Liver
European Biotechnology Magazine Germany Overview RNA therapeutics are entering a 'second act' after the success of mRNA vaccines during the COVID-19 pandemic, with a critical focus on developing effective delivery technologies to extrahe... -
Antibody-Drug Conjugates Evolve into Smart Chemotherapy, Datroway Gains FDA Approval for Metastatic Triple-Negative Breast Cancer
Karchem Consulting USA Overview Antibody-Drug Conjugates (ADCs) are evolving into next-generation 'smart chemotherapies' by integrating precise targeting with innovative linker-payload technologies. Novel drug classes like nucleic acid a...
